-
Type:
Change Request
-
Resolution: Persuasive with Modification
-
Priority:
Medium
-
US Core (FHIR)
-
3.1.1
-
Cross-Group Projects
-
US Core AllergyIntolerance Profile
-
(NA)
-
-
Brett Marquard/Gay Dolin: 10-0-0
-
Correction
-
Compatible, substantive
The value set Common substances for allergy and intolerance documentation including refutations is defined in VSAC here - author definition mode as a grouping value set that includes member value set Common drug classes for allergy and intolerance documentation. That member value set is based on assuming the "correct" way to use SNOMED CT to represent drug classes was via the substance hierarchy. More recently ONC and NLM have used the SCT product hierarchy for drug classes. See the ONC ISA and note that NLM RxClass (and therefore RxMix) link RxNorm drugs via the product hierarchy (see Penicillin antibiotic product example.) Based on the HL7 Cross Paradigm Specification: Allergy and Intolerance Substance Value Set(s) Definition, Release 1 specification, work was completed to create a new value set of SCT product classes needed for C-CDA that included drug classes needed to represent the top 95% in the HL7 spec. That work is documented here and uses the new SCT drug class value set Medication drug class for allergen intolerance SCT.
This request is to replace the member value set "Common drug classes for allergy and intolerance documentation" 2.16.840.1.113762.1.4.1186.2 that is in grouper Common substances for allergy and intolerance documentation including refutations with the value set Medication drug class for allergen intolerance SCT (expansion here.) Then update Common substances for allergy and intolerance documentation including refutations in the USCore build to align with this change.
- mentioned in
-
Page Loading...